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Human recombinant myclopcroxidasc was cvaluatcd in a cell-fret system for its inactivation properties on the replication of human immunodcfi- 
cicncy virus, HTLV-III,,. In the presence of a hydrogen peroxide gcneruting system (glucose and glucose oxidase) and sodium thiocyanate, the 
recombinant enzyme inhibited virus-induced syncytium formation and viral replication without causing any cytoprthic effects on SupTl reporter 
cells. In addition, U937 monocytoid cells. chrcnicully infcctcd with HIVI, were exposed to recombinant myelopcroxidase (IO U/ml) and monitored 
during 42 h for the accumulation of intracellular ~24 viral untigcn. Under thcsc conditions, the recombinant enzyme significantly reduced 
intracellular viral replication without affecting cell viability. 
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I. INTRODUCTION 
Inhibition of HIV infection by a variety of chemical 
drugs has been reported; in many cases, the therapeuti- 
cal use of these compounds is hampered by toxic side 
effects [!I. The need for new antiviral agents, devoid of 
these problems, is more pressing than ever in view of the 
widespread occurrence of AIDS. Human polymor- 
phonuclear leukocytes might be the source of such safe 
and efficient, albeit non-specific, agents. Indeed, neutro- 
phils contain in their azurophilic granules an enzyme, 
myeloperoxidase, which displays strong inhibitory 
properties towards a large number of micro-organisms. 
including fungi and viruses [2-4]. In the presence of 
hydrogen peroxide, MPO catalyzes the oxidation of hal- 
ides, or of a physiological pseudohalide such as thiocy- 
anate [5], which in turn generates microbicidal com- 
pounds causing irreversible damage to the targets [6]. In 
mononuclear cells, production of MPO is restricted to 
fresh monocytes and is lost when these cells differentiate 
into resident issue macrophages. These cells, however, 
still possess the hydrogen peroxidase generating system 
[71. 
Macrophages are major in vivo reservoirs for human 
immuno deficiency viruses [8] and may be vectors for 
the spread of infection to different tissues. It is thus 
anticipated that any appropriate antiviral agent targ- 
Ahbre~+u~iottx MPO. myeloperoxidase (EC I. I I, 1.7): recMP0. re- 
combinant myeloperoxidasc. 
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etted to these infected cells may be able to prevent he 
dissemination of infectious particles. In this respect, 
MPO could be of interest since it has been shown to be 
internalized by macrophages in culture while maintain- 
ing its peroxidase activity [9]. 
MPO has usually been isolated from human poly 
morphonuclear cells or from the established HL60 pro- 
myelocytic ell line [ IO,1 11. These sources, however. are 
inappropriate for large-scale preparation of the enzyme 
and have been replaced recently by engineered CHO 
cells overproducing recombinant myeloperoxidase [ 121. 
Although this product corresponds to the unprocessed 
precursor of human myetopcroxidase, it displays bio- 
physical and biochemical properties identical to those 
of the natural enzyme, including potent antibacterial 
activity [121. In order to check if recombinant MPO also 
exhibits antiviral properties, we investigated its ability 
to inactivate the human immunodeficicncy virus either 
in vitro when used in conjunction with the appropriate 
substrates or inside chronically infected U937 monocy- 
toid cells in culture. 
2. MATERIALS AND METHODS 
2. I. Yiriddd ocriviry yf rccMP0 in a cc~i$k~ syssrers 
Inactivation assays proceeded as follows: an aliquot ofa HTLV-iIlu 
viral suspension at 1.1 x IO’ TClDJml (60 yl). derived from persis- 
tently infcctcd MOLT-3 cells [ 131, was incubated for I5 min at 37OC 
in the presence ofglucose and &~cosc oxidase (the hydrogen peroxide 
gcncrating system), sodium thiocyanate and recombinant MPO (0.8 
U/p& [ 121). These components. prcparcd as stock saktions in complete 
culture medium (RPM1 medium. Gibeo; 5% fetal calf serum. Seralab) 
were used tither separately or in combination and at various concen- 
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Irations, Wbcn necessary, volumes were adjusted to 500 pl with com- 
plete culture medium. Mixtures were then transferred onto SupTl 
reporter cell pellets (2a10b; [I41 und J. Hoxic, Univ, of Pennsylvania, 
USA) and further incubated for 45 min at 37OC. Cells were washed 
twice with complete cukure medium, resuspended in IO ml of fresh 
medium (2.10’ cells/ml) and allowed to grow at 37OC for up to ten 
days. Monitoring of cell cultures was done under the microscope at 
days 3. 5 and 7 post-infection i order to evaluate the cytopathic effect. 
On the same days and on day 10 post-infection, 0.5 ml of the cell 
suspensions was collected and frozen unlil USC. Samples wcrc then 
ussaycd for the p24 antigen using a murine monoclonal anti ~24 
antibody (NEN-DuPont, USA) and human anti-HIV immunoglo- 
bulinscouplcd to biotin. Complexes were detected with a streptavidin- 
horseradish pcroxidasc onjugate (Amersham) and the orthophen- 
ylcne diamine chromogenic substrate (Sigma). Optical densities were 
recorded at 490 nm. 
2.2. Eiricl~~l acliriy of rccMP0 011 NIYI-infwrrd U937 cclh 
The humun CD4+ monocytoid cell line U937 (a gift from Dr. Sbcr- 
man. Marseille, France) was maintained in RPM1 medium supple- 
mented with 10% fetal calfserum and 1% PSN (penicillin, strcptomy- 
tin and neomycin antibiotic mixture, Gibco), The permanent ARV-4 
cell line chronically producing HIV1 was used as a source or virus (a 
gift from Dr. J. Levy, San Francisco, USA). 10” U937 cells, prealably 
exposed to polybrcnc (2 pgrnl) for 30 min, were pelleted then incu- 
bated for 2 h in I ml of an ARV4 cell supernatant containing 160.000 
pg of p24 antigen. Cells were washed twice with Hanks butTcr (Gibco) 
and cultivated for three days. After washing. cells were exposed to 
recMP0 at 10 U/ml medium and further cultivated for 48 h. Aliquots 
of the cells were collected at various times after addition of recMPG. 
washed three times, lyzcd and assayed 1’01 the p24 antigen content, 
usinS the Abbott Laboratories antigen capture assuy. Cell viability 
was assayed by the Trypdn blue exclusion method. 
3. RESULTS 
3.1 Viricidal activiry of recMP0 itt a cekfiee systettt 
Preliminary experiments consisted of testing if any of 
the separate components of the assay system could by 
themselves inhibit the development of the immunode- 
fiency virus. In fact, neither glucose, glucose oxidase. 
sodium thiocyanate, nor recMP0 had any significant 
effect on syncytium formation in virus-infected reporter 
cells and on viral replication (data not shown). Optimal 
concentrations of glucose oxidase, the enzymatic part of 
the H& generating system, were then determined. It 
turned out that 60 mU/ml of the enzyme were generat- 
ing excess hydrogen peroxide and were leading to cell 
death. Actual infection experiments were thus per- 
formed using either 0,6 or 1 mu/ml of glucose oxidase 
in the presence of lye glucose and 20 lug/ml of NaSCN. 
Three recMP0 concentrations, 8, 16 and 32 U/ml, were 
tested. As seen in Fig. I and Table I, in each case, virus- 
induced cytopathic effects, as seen under the micro- 
scope, and viral replication, as measured by a ~24 anti- 
gen capture assay and expressed as variations in ODdg0, 
were significantly reduced or totally suppressed. It ap- 
peared that glucose oxidase at 0.6 mu/ml did not gener- 
ate enough H,Os for full efficacy of recMP0 whereas 
this was achieved with a tenfold increase in glucose 
oxidase. As expected, the effects of recMP0 were 
strictly dependent on the simultaneous presence of hy- 
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Fig. I. Inhibition of HTLV-III,, replication, in vitro, by human 
rccMP0. The HTLV-III,, virus (I200 T-cell infectious dosis 50%) was 
incubated with recMP0 (8 U/ml) in the presence of sodium thiocya- 
nate and a hydrogen peroxide generating system. The treated virus 
wus then used to inl’cct reporter SupTl human cells. Growth of the 
virus in infected cells was monitored l’or ten days using a p24 antigen 
capture assay. Data arc expressed in milliunits ODdW. (o), positive 
control. reporter cells infected with untreated virus; (o), negative con- 
trol, uninfected reporter cells; (o), reporter cells infected with the 
HTLV-IIIu virus treated with 8 U/ml of recMP0 in the presence or 
0.G mUlml of glucose oxidase, 1% glucose and 20 ,ugIml NaSCN; 
(m), same conditions as above, except he concentration of glucose 
oxidase (6 mU/ml). 
drogen peroxide, as provided by the generating system, 
and of sodium thiocyanate. 
3.2. Viricidal ef$xr of recMP0 on itztrucelltdar HIV1 
rephuion 
Preliminary experiments consisted of testing the ef- 
fect of recMP0 on the growth of HIV1 infected U937 
cells. Over a time span of 72 h, recMP0 at a final 
concentration of 12 U/ml in the culture medium did not 
affect cell viability. Starting from 2.10’ viable cells/ml, 
the culture reached lo6 viable cells/ml after three days 
in the presence or absence of the recombinant enzyme. 
The subsequent experiment was designed to evaluate 
the effect of recMP0 on the intracellular eplication of 
the virus. To this end, U937 cells infected with HIV1 
were washed to remove the extracellular virus, then 
exposed to recMP0 at 10 U/ml in culture medium and 
further incubated. Cells were collected at 2,6, 20,24 and 
48 h after addition of recMP0, washed, tested again for 
viability, lyzed and assayed for the intracellular p24 
antigen content. As seen in Fig. 2, viral replication in 
U937 ce!!s was prevented by recMP0 for at least 20 h. 
(Beyond that period, viral replication in untreated in- 
fected cells started to decline.) 
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Fig. 2. Inhibhion of viral replicauon by rccMP0 in chronicully in- 
fected U937 cells. U937 monocyioid cells chronically infccuzd with 
HIV1 (ace section 2) wcrccxposcdto IO U/mlofrccMPOin theculture 
medium. Samples were collected at various times. lysed and assayed 
for p24 contem, Data are cxprcssed in pg p24 per IO” viable cells. (0). 
umreated infccled U937 cells; (I). rccMPO.ircated infected U937 
cells. 
4. DISCUSSION 
The data show that human recombinant MPO. in the 
presence of appropriate substrates, irreversibly inacti- 
vates the HTLV-III,, virus in vitro, as was recently 
shown also for the natural enzyme [lS]. In addition, 
recMP0 appears to inhibit intrclcellular viral replication 
in U937 monocytoid cells in culture, chronically in- 
fected with HIV1 I Lactopcroxidasc-mediated killing of 
enveloppcd viruses has already been documented [16- 
181. MPO, however. offers several advantages over 
other peroxidases as a potential in vivo therapeutic 
agent. As a natural human enzyme, it is expected to he 
non-immunogenic and non-toxic; in addition, it is now 
available on a iarge scale via engineered CHO cells in 
culture [12]. MPO functions naturally in the biological 
environment of monocytes, which provide the appropri- 
ate substances, NADPH, NADPH oxidase and halide 
ions, for optimal enzyme activity [2,3,5]. Macrophages, 
the differentiated form of monocytes, although lacking 
MPO activity, still present he same hydrogen peroxide 
generating system 171. Specific targetting of recMP0 to 
macrophages could thus restore a strong oxidative ca- 
pability, which would help fighting off infections of 
these cells, In conclusion, the results presented here war- 
rant further detailed studies on the role of recMP0 as 
an efficient antiviral agent in vivo. 
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Table I 
Antiviral activity of numan recombinant mycloperoxidasc in a cells 
free system. 
Assay Monhoring Days post infection 
3 5 7 IO 
Cotm?l,v 
l-l Sup1 Reporter cells, CPE (+) + nd 
+ virus OD,, 55 144 &+l 975 
T2 TI .t glucose CPE (+) + 
oxidasc 0.6 mU/ml ODdw 92 184 & ::o 
T3 TI + glucose CPE (+) + nd 
oxidasc 6 mu/ml ODdw 97 368 ;;5 775 
Curn(l/elc .s_r.srotr,s 
T4 Glucose oxidase CPE - - (+) nd 
0.6 mU/ml 
and rccMP0 OD,, 7 3 22 I89 
8 U/ml % inhib. 92.4 98.4 94.5 74.8 
T5 T4 whh rccMP0 CPE - - (+) nd 
I6 U/ml OD,, I2 0 29 328 
% inhib. 87 100 92.8 56,2 
T6 T4 with recMP0 CPE - - (+) nd 
32 U/ml OD,, 5 IO I7 240 
% inhib, 94.5 94.5 95.8 68 
T7-T9 Glucose oxidaac CPE - - - nd 
6 mU/mt OD,u, 0 0 0 0 
and recMP0 at 8 inhib. loo loo 100 100 
8, 16. or 32 U/ml 
CPE: rylopalhic cflecls observed under the microscope; -: no 
syncytia: (+): ti few syncyiiuc: + and *+: increase in siae and number 
of syncyliac. 
OD,,,: optical dcnsitics in milliunits at 490 nm. 
nd: no! done. 
Complete systems: indicates the presence. in the mixtures. of HTLV. 
1111, virus, SupTl cells. glucose, 8lucosc oxidasc, sodium thiocyanatc 
and rccMP0. 
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